Premium
A double‐blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis : a multicentre trial
Author(s) -
MÖSSNER J.,
HÖLSCHER† A. H.,
HERZ R.,
SCHNEIDER A.
Publication year - 1995
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1995.tb00388.x
Subject(s) - omeprazole , pantoprazole , medicine , gastroenterology , reflux , double blind , esophagitis , proton pump inhibitor , reflux esophagitis , esophageal disease , placebo , esophagus , disease , pathology , alternative medicine
SUMMARY Background : Pantoprazole is a new substituted benzimidazole which is a potent inhibitor of gastric acid secretion by its action upon H + ,K + ‐ATPase. Aim :To compare pantoprazole 40 mg with omeprazol 20 mg as once daily dosing in the treatment of reflux oesophagitis (grades II and III). Methods : This double‐blind, randomized, multicentre study included 286 patients. Patients were reendoscoped after 4 weeks, and continued to receive a further 4 weeks of treatment if they were not healed a this time. Results : After 4 weeks of treatment, complete healing occurred in 126/170 (74%) patients in the pantoprazole group and in 67/86 (78%) patients in the omeprazole group (per‐protocol analysis). At 8 weeks, the corresponding healing rates were 153/170 (90%) and 81/86 (94%). The differences between the treatment groups were not significant ( P = 0.57 and 0.34). Improvement in the principal symptoms of reflux oesophagitis was also very similar between the treatment groups, with 59% and 69% at 2 weeks, and 83% and 86% at 4 weeks, respectively, being free from any individual symptom. Both treatments were well tolerated. Conclusions : This study has shown pantoprazole and omeprazole to be similarly effective and well tolerated in the treatment of mild to moderate reflux oesophagitis.